COMMUNIQUÉS West-GlobeNewswire

-
HealthLynked Announces Exciting New Update with HealthLynked 3.2.0 - Transforming Patient-Care Through Innovation
26/03/2024 -
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
26/03/2024 -
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
26/03/2024 -
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
26/03/2024 -
Laverock Therapeutics announces appointment of Ali Elsley as Finance Director and expansion of team
26/03/2024 -
Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2
26/03/2024 -
Annual General Meeting 2024: Tecan proposes election of an additional member of the Board of Directors and various amendments to the Articles of Incorporation
26/03/2024 -
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
26/03/2024 -
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
26/03/2024 -
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
26/03/2024 -
Valneva lance un essai de Phase 1 sur son candidat vaccin de deuxième génération contre le virus Zika
26/03/2024 -
CARBIOS joins Paris Good Fashion to accelerate textile circularity and contribute to more sustainable fashion
26/03/2024 -
CARBIOS rejoint Paris Good Fashion pour accélérer la circularité des textiles et contribuer à une mode plus durable
26/03/2024 -
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
26/03/2024 -
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
25/03/2024 -
Precipio Announces Year end 2023 Shareholder Update Call
25/03/2024 -
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
25/03/2024 -
Ibogaine By David Dardashti Explains the Legal Status of Ibogaine
25/03/2024 -
Goodness Growth Holdings Reschedules Fourth Quarter and Full Year 2023 Results Call to April 1, 2024
25/03/2024
Pages